Funding for this research was provided by:
Klinikum rechts der Isar der Technischen Universität München
Received: 17 November 2021
Accepted: 8 April 2022
First Online: 26 April 2022
: The study was submitted to and approved by the Ethics Committee of the Technical University of Munich, Munich, Germany (Project Code: 312/19S). All participants provided written consent for the research use of their data, and the study was performed according to the principles of the Declaration of Helsinki.
: Not applicable.
: UE is an employee of Roche Diagnostics GmbH. OG received consulting fees from Eli Lilly, performed prescreening activities for Julius Clinical/Fujifilm Toyama Chemical, and received grants to his institution from Actelion. TG received consulting fees from Abbvie, Anavex, Biogen, Bracket, Eli Lilly, Functional Neuromodulation Ltd., IQVIA/Quintiles, Novartis, Novo Nordisk, Nui Care, Roche Pharma, Toyama, and Vivoryon Therapeutics; lecture fees from Actelion, B. Braun, Biogen, Eli Lilly, Life Molecular Imaging, Novartis, Parexel, and Roche Pharma; and grants to his institution from Actelion and Novartis. The other authors declare that they have no competing interests.